 |
市場調査レポート
モノクロナール抗体に関する各種提携契約：契約条件・合意内容Global Monoclonal Antibody Partnering Terms and Agreements 2010-2017: Deal Trends, Players and Financials |
||||||
| 発行 | Current Partnering, a division of Wildwood Ventures Limited | 商品コード | 256416 | ||||
| 出版日 | ページ情報 | 英文 500+ Pages 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| モノクロナール抗体に関する各種提携契約：契約条件・合意内容 Global Monoclonal Antibody Partnering Terms and Agreements 2010-2017: Deal Trends, Players and Financials | ||
| 出版日: 2017年09月08日 | ページ情報: 英文 500+ Pages |
|
当レポートでは、モノクロナール抗体に関する各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・治療分野・技術タイプ別のディレクトリなどをまとめています。
※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。
The ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017: Deal trends, players, financials and forecasts ’ report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.
‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 ’ provides the reader with the following key benefits:
‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 ’ is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.
‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 ’ includes:
In ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2017 ’, the available deals are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2017 ’ report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:
